• Search History (Register)
  • MeSH Browser
  • [Clear]
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Canada
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [3358 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Debridement procedures for managing diabetic foot ulcers: a review of clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening tools to identify adults with cognitive impairment associated with dementia: diagnostic accuracy
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) TECNIS® or Acrysof® soft intraocular lenses for patients undergoing cataract surgery: benefits and harms, clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nabilone for non-chemotherapy-associated nausea and weight loss due to medical conditions: a review of the clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment strategies for patients with renal colic: a review of the comparative clinical and cost-effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Wireless device use and patient monitoring equipment in any healthcare delivery setting: a review of safety and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Drug therapy for chronic thromboembolic pulmonary hypertension: a review of the comparative clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatments for constipation: a review of systematic reviews
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Infection prevention and control procedures for carbapenemase-producing Enterobacteriaceae: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nicotine replacement therapy for smoking cessation or reduction: a review of the clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Acyclovir versus valacyclovir for herpes virus in children and pregnant women: a review of the clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Dexmedetomidine for sedation of patients in the ICU or PICU: review of clinical effectiveness and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Obstetric, neonatal, and child outcomes for women with previous bariatric surgery: a review of the clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Essential oil products for disinfection: clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Sofosbuvir (Sovaldi — Gilead Sciences Canada, Inc.) indication: chronic hepatitis C infection
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Aripiprazole (Abilify — Bristol-Myers Squibb Canada) new indication: major depressive disorder
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Ulipristal Acetate (Fibristal - Actavis Specialty Pharmaceuticals Co.) indication: uterine fibroids
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ustekinumab (Stelara — Janssen Inc.) indication: psoriatic arthritis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Subsequent entry biologics — emerging trends in regulatory and health technology assessment frameworks
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Aflibercept (Eylea — Bayer Inc.) indication: wet age-related macular degeneration
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Goal setting tools for children: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Stiripentol (Diacomit — Biocodex SA) indication: severe myoclonic epilepsy in infancy (Dravet syndrome)
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Maxillary artery ligation for the treatment of cluster or migraine headaches: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Hemodialysis chairs versus beds for patients at out-patient clinics: clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Pharmacoeconomic review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography-guided brachytherapy treatment in the operating room: clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Guanfacine hydrochloride extended release (Intuniv XR — Shire Canada Inc.) indication: attention deficit hyperactivity disorder
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Timothy grass standardized allergenic extract (Grastek — Merck Canada Inc.) indication: allergic rhinitis (grass pollen)
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Fluticasone furoate /vilanterol (Breo Ellipta — GlaxoSmithKline) indication: chronic obstructive pulmonary disease
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Dolutegravir (Tivicay — ViiV Healthcare ULC) indication: HIV infection
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nephrostomy and biliary tube management: a review of the clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Natural sheepskins for the treatment of pressure ulcers: clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Regular health monitoring for older adults: clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Golimumab (Simponi IV — Janssen Inc.) indication: rheumatoid arthritis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Riociguat (Adempas — Bayer HealthCare) indication: chronic thromboembolic pulmonary hypertension
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Use of azathioprine in adults: safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Negative pressure wound therapy for managing diabetic foot ulcers: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Virtual reality exposure therapy for adults with post-traumatic stress disorder: a review of the clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Hyperbaric oxygen therapy for adults with mental illness: a review of the clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Normothermia versus therapeutic hypothermia for adult patients after cardiac arrest: clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Growth measurement of infants and children: guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Neurofeedback and biofeedback for mood and anxiety disorders: a review of the clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Admission of patients with suspected or active infection to oncology units: clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Breast reduction surgery for hypermastia: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Endovascular thermal ablation technologies for treatment of varicose veins: a review of clinical effectiveness, safety, cost-effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Wear compliance and donning/doffing of respiratory protection for bioaerosols or infectious agents: a review of the effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Respiratory precautions for protection from bioaerosols or infectious agents: a review of the clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Motor interventions for autism spectrum disorder in children: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Oral ginger for the management of chemotherapy-induced nausea and vomiting in pediatric patients: clinical effectiveness and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Long-term use of bevacizumab for the treatment of age-related macular degeneration: safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Methylene blue for the prevention and treatment of ifosfamide-induced encephalopathy: clinical effectiveness and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Nasogastric feeding tubes versus percutaneous endoscopic gastrostomy for patients with head or neck cancer: a review of clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Thrombophilia testing for women who have had pregnancy loss: clinical evidence, cost-effectiveness, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Bone marrow aspiration or biopsy for patients with immune thrombocytopenia: clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Patient-controlled analgesia for acute injury transfers: a review of the clinical effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Ondansetron for post-operative nausea and vomiting in elderly patients: clinical effectiveness and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Hand sanitizers for the prevention of infection transmission: comparative clinical effectiveness and clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Cardiopulmonary resuscitation for elderly adults in chronic or long-term care: clinical effectiveness and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Cataract surgery performed under local anaesthesia: guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Medical marijuana for the treatment of mental illness: clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Immersion in water during active labour and delivery: clinical effectiveness, safety, and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Short- and long-term use of benzodiazepines in patients with generalized anxiety disorder: a review of guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Simethicone administration during endoscopic procedures: clinical evidence and guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Saxagliptin + metformin (Komboglyze — AstraZeneca) indication: type 2 diabetes mellitus
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Simeprevir (Galexos — Janssen Inc.) indication: chronic hepatitis C genotype 1 infection
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Aclidinium bromide (Tudorza Genuair — Almirall Canada Ltd.) indication: chronic obstructive pulmonary disease
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) OnabotulinumtoxinA (Botox — Allergan Inc.) indication: chronic migraine
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Rotigotine (Neupro — UCB Canada Inc.) indication: idiopathic parkinson disease (early and advanced)
2014     Health Quality Ontario (HQO) Robotic-assisted minimally invasive prostatectomy: OHTAC recommendation
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Eplerenone (Inspra — Pfizer Canada Inc.) new indication: NYHA class II heart failure
2014     Health Quality Ontario (HQO) The appropriate use of neuroimaging in the diagnostic work-up of dementia: OHTAC recommendation
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Use of new versus refurbished surgical tables: comparative clinical effectiveness and guidelines
2014     Medical Advisory Secretariat (MAS) Multiple intravenous infusions
2014     Health Quality Ontario (HQO) Frequency of testing for dyslipidemia: OHTAC recommendation
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Oral progesterone for the treatment of menopausal symptoms: clinical evidence
2014     Health Quality Ontario (HQO) Preoperative resting echocardiography for noncardiac surgery
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Obesity management interventions delivered in primary care for patients with osteoarthritis: a review of clinical effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography imaging for the diagnosis of renal colic: a review of clinical and cost-effectiveness
2014     Health Quality Ontario (HQO) Preoperative cardiac stress tests for noncardiac surgery
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Smoking cessation prior to surgery: clinical evidence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening tools to identify adults with cognitive impairment associated with a cerebrovascular accident or traumatic brain injury: diagnostic accuracy
2014     Health Quality Ontario (HQO) Preoperative consultations
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Prevention of dehydration in geriatric patients in long-term care: guidelines
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Psychiatrist-led care of patients with dementia and psychiatric disorders in long-term care settings: clinical evidence and guidelines
2014     Health Quality Ontario (HQO) Update on physiotherapy rehabilitation after total knee or hip replacement
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) The use of endotracheal tubes with subglottic secretion drainage to prevent ventilator-associated pneumonia: clinical effectiveness and safety
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Portable ultrasound devices for obstetrical or prenatal assessment in rural or remote settings: a review of the diagnostic accuracy
2014     Health Quality Ontario (HQO) Parathyroid hormone